Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    356 result(s) found for: Agonists. Displaying page 2 of 18.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-004825-29 Sponsor Protocol Number: IIS-2011-01 Start Date*: 2011-11-30
    Sponsor Name:Instituto de Investigaciones del Sueño
    Full Title: TREATMENT WITH ROTIGOTINE OF RLS PATIENTS WITH AN INSUFFICIENT RESPONSE TO DOPAMINE AGONIST WITH INTERMEDIATE HALF-LIFE.
    Medical condition: Restless Legs Syndrom
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021403-24 Sponsor Protocol Number: 001 Start Date*: 2010-11-10
    Sponsor Name:North Lincolnshire and Goole NHS Foundation Trust
    Full Title: A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia.
    Medical condition: Hyperprolactinaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020737 Hyperprolactinaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002094-46 Sponsor Protocol Number: FB/PS/14/160/06 Start Date*: 2006-06-26
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Single blind, randomized, crossover, repeated dose, pharmacokinetic and pharmacodynamic interaction study of CHF 4226 HFA and Extra-fine BUD HFA in asthmatic patients
    Medical condition: Asthmatics patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003142-34 Sponsor Protocol Number: 2005-061 Start Date*: 2005-09-20
    Sponsor Name:Respiratory and Allergy Research Unit
    Full Title: Elite sport and development of asthma: Airway inflammation and treatment.
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005034-39 Sponsor Protocol Number: Start Date*: 2005-05-17
    Sponsor Name:Queen Elizabeth Hospital
    Full Title: Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease
    Medical condition: Idiopathic Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001642-18 Sponsor Protocol Number: WP3 Start Date*: 2019-12-05
    Sponsor Name:Department of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect on the ocular surface when treating glaucoma with eye drops: an investigation of the conjunctival goblet cells
    Medical condition: Open angular glaucoma and ocular hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016375-30 Sponsor Protocol Number: MK-0462-086 Start Date*: 2010-02-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura
    Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005385-38 Sponsor Protocol Number: GFT505-315-1 Start Date*: 2016-03-04
    Sponsor Name:Genfit SA
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis.
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) and fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10016642 Fibrosis PT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Completed) CZ (Prematurely Ended) SE (Completed) IT (Prematurely Ended) PT (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000678-57 Sponsor Protocol Number: S308.3.003 Start Date*: 2007-06-18
    Sponsor Name:Solvay pharmaceuticals
    Full Title: A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Pa...
    Medical condition: Parkinson 's Disease early stage
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) EE (Completed) LT (Completed) DE (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002122-67 Sponsor Protocol Number: 1211 Start Date*: 2013-12-05
    Sponsor Name:EORTC
    Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
    Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016374-32 Sponsor Protocol Number: MK-0462-082 Start Date*: 2010-02-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adole...
    Medical condition: Acute treatment of migraine, with or without aura, in children and adolescents, ages 6 to 17 years, who do not have a satisfactory response to prior treatment with nonsteroidal anti-inflammatory dr...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) BE (Completed) ES (Completed) EE (Completed) LV (Completed) SE (Completed) FR (Completed) DK (Completed) GB (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000899-15 Sponsor Protocol Number: EORTC-1531-ROG Start Date*: 2019-12-03
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study
    Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001030-33 Sponsor Protocol Number: MRCPR09 Start Date*: 2005-11-23
    Sponsor Name:University College London
    Full Title: PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.
    Medical condition: Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-000512-17 Sponsor Protocol Number: 20040138 Start Date*: 2004-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
    Medical condition: Bone loss in pateints undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049470 Bone density decreased LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001650-98 Sponsor Protocol Number: AC1802 Start Date*: 2018-12-10
    Sponsor Name:University of Edinburgh and NHS Lothian [...]
    1. University of Edinburgh and NHS Lothian
    2. NHS Lothian
    Full Title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost...
    Medical condition: Any patient requiring intensive care treatment due to critical illness.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10033305 Oversedation LLT
    20.0 10029205 - Nervous system disorders 10039897 Sedation PT
    21.1 100000004865 10049124 Sedation during medical procedure LLT
    20.1 10029205 - Nervous system disorders 10039898 Sedation excessive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002832-15 Sponsor Protocol Number: 49916 Start Date*: 2014-12-17
    Sponsor Name:VU university medical center
    Full Title: Ulipristal versus Gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy: a double blind randomized controlled trial
    Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard which removes the fibroids entirely, preferably lapa...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004943-12 Sponsor Protocol Number: S308.3.010 Start Date*: 2008-11-24
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration...
    Medical condition: Early Stage Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004898-32 Sponsor Protocol Number: SAM103848 Start Date*: 2016-12-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Pediatric Asthma Clinical Effectiveness study (PEACE). A Randomized, Double-Blind, Double Dummy, Parallel Group comparative clinical study of Salmeterol/Fluticasone propionate Inhalation Powder (50...
    Medical condition: Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002836-25 Sponsor Protocol Number: QGUY/2004/IL 4-13/01 Start Date*: 2004-12-15
    Sponsor Name:Aerovance Inc.
    Full Title: A Phase IIa Study To Investigate The Effects of AER 001on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.
    Medical condition: Asthma is characterised by an infiltration of the bronchial mucosa with activated T-lymphocytes (T-cells), eosinophils, and to a lessor extent polymorphonuclear leukocytes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004614-16 Sponsor Protocol Number: DIA-ALE-2004-01 Start Date*: 2005-09-29
    Sponsor Name:DIATER LABORATORIES S.A.
    Full Title: Alternaria alternata inmunotherapy effects on AMP and methacholine bronchial answer and on inflammation markers in exhaled air (nitric oxide) and in condensated air (pH and hydrogen peroxide) in a...
    Medical condition: Asthma and allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 00:23:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA